Pharmaceuticals
LISCure Biosciences Successfully Raises $21 million in Series B Funding
SEOUL, South Korea, Feb. 26, 2021 /PRNewswire/ -- On February 25th, 2021, LISCure Biosciences Inc., a biotech company that focuses on developing bacteria-mediated immunotherapy, announced that it has successfully completed $21 million of a Series B funding round. Participants include institutional...
2021-02-26 22:00
3324
Alterity to present at the 7th International Congress of Multiple System Atrophy
MELBOURNE, Australia and SAN FRANCISCO, Feb. 26, 2021 /PRNewswire/ -- Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format fromFebruary 26-...
2021-02-26 20:45
6298
Tigermed Supported and Delivered Clinical Study of CanSino COVID-19 Vaccine as Clinical Contract Research Organization
HANGZHOU, China, Feb. 26, 2021 /PRNewswire/ -- China National Medical Products Administration (NMPA) announced onFebruary 25 to grant conditional marketing authorization of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) (the "Ad5-nCoV", trade name: Convidecia™). CanSino Biologics Inc. an...
2021-02-26 16:36
5237
I-Mab Announces First Patient Dosed in China Phase 3 Study of Eftansomatropin Alfa in Pediatric Patients with Growth Hormone Deficiency
SHANGHAI and GAITHERSBURG, Md., Feb. 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the first patient has been dosed in the phase 3 piv...
2021-02-25 21:00
4889
I-Mab Announces Upcoming Participation at March Conferences
SHANGHAI and GAITHERSBURG, Md., Feb. 24, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in March....
2021-02-24 21:00
4818
Gracell Biotechnologies to Report Fourth Quarter and Fiscal 2020 Financial Results on Tuesday, March 9, 2021
SUZHOU and SHANGHAI, China, Feb. 23, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies, today announced that it plans to release ...
2021-02-23 21:00
7951
Positive BNC210 7-Day Dosing Pharmacokinetic Study Exceeds Blood Exposure Projected for Phase 2b PTSD Trial
* BNC210 novel oral tablet formulation (900 mg given twice daily) exceeds blood exposure projected for upcoming Phase2b PTSD trial * BNC210 Phase 2b PTSD trial on target for start in mid-2021 with final dose selected ADELAIDE, Australia, Feb. 22, 2021 /PRNewswire/ -- Bionomics Limited (ASX: B...
2021-02-22 19:00
3225
Completion of Patients' Recruitment for Proxalutamide's COVID-19 Hospitalised Study
SUZHOU, China, Feb.22, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited (HKEX:9939) is pleased to announce that the clinical trial of Proxalutamide for the treatment of hospitalised COVID-19 patients inBrazil completed the recruitment of 588 patients. The data of the clinical trial is expected ...
2021-02-22 17:14
3207
China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split
TAIZHOU, China, Feb. 19, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company"), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces ("TCMPs"), including Ad...
2021-02-19 21:00
5733
Psychobiotic PS128 consumption shows benefits to Parkinson's symptoms in new clinical study
TAIPEI, Feb. 18, 2021 /PRNewswire/ -- Bened Biomedical, a leading Taiwanese probiotic company, has announced a successful clinical study for its PS128 psychobiotic in treating symptoms of Parkinson's disease (PD). The study was led by a neurologist, Dr.Chin-Song Lu, a renowned researcher for PD i...
2021-02-19 12:07
1773
GenScript ProBio and Neoletix Announce Successful Completion of 200-Liter GMP Production Runs of Recombinant Coagulation FVIII Based on a Novel Production Technology
NANJING, China, Feb. 18, 2021 /PRNewswire/ -- On February 7th, 2021, GenScript ProBio announced that it has successfully completed 3 X 200 L GMP production runs of recombinant human factor VIII (rhFVIII) for Beijing Neoletix Biological Technology Co., Ltd. (Neoletix). InMay 2019, GenScript ProBio...
2021-02-18 22:00
1924
Everest Medicines Appoints Kevin Guo as Chief Commercial Officer
SHANGHAI, Feb. 18, 2021 /PRNewswire/ -- Everest Medicines
2021-02-18 12:21
3580
Joint feasibility assessment of Bionomics' BNC210 and EmpathBio's MDMA derivative EMP-01 treatment regimen for PTSD
ADELAIDE, Australia, Feb. 17, 2021 /PRNewswire/ -- Bionomics Limited (ASX: BNO, OTCQB: BNOEF,Germany: AU000000BNO5) (Bionomics) today announced that it has entered into a Memorandum of Understanding with EmpathBio Inc (EmpathBio), a wholly owned subsidiary ofGermany-based CNS clinical development...
2021-02-17 19:00
5966
China SXT Pharmaceuticals, Inc. Enters into Non-Binding LOI to Acquire Jiangsu Renji Pharmaceutical Chain Co., Ltd.
TAIZHOU, China, Feb. 11, 2021 /PRNewswire/ -- China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) ("China SXT" or the "Company") announced today that it has entered into a non-binding letter of intent with Jiangsu Renji Pharmaceutical Chain Co., Ltd. ("Renji Chain"). Pursuant to the terms of the LOI,...
2021-02-11 21:00
3797
GenScript Receives FDA Emergency Use Authorization for Use of cPass(TM) SARS-CoV-2 Neutralization Antibody Test in Convalescent Plasma Screening
PISCATAWAY, N.J., Feb. 11, 2021 /PRNewswire/ -- GenScript USA Inc
2021-02-11 20:30
1550
Transcenta Holding Announces Appointment of Dr. Michael Shi as Executive Vice President, Head of Global R&D and Chief Medical Officer
SUZHOU, China, Feb. 10, 2021 /PRNewswire/ -- Transcenta Holding Limited (Transcenta), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, today announced the appointment of Dr.Michael Shi as Executive Vic...
2021-02-11 08:00
1733
I-Mab Announces China NMPA Clearance for Phase 1 Study of TJ210/MOR210 in Patients with Advanced Solid Tumors
SHANGHAI and GAITHERSBURG, Md., Feb. 10, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China N...
2021-02-10 21:00
5366
Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial
BEDMINSTER, N.J. and SINGAPORE, Feb. 10, 2021 /PRNewswire/ -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the successful completion of dosing of the first pati...
2021-02-10 19:12
1824
$16 Million Capital Raise to Progress Bionomics BNC210 PTSD Trial
* Commitments received for a placement of A$15,991,634 at A$0.145 per share * Significant participation from North American and European institutional and sophisticated investors * This capital raising enables proceeding with the Phase 2b PTSD trial in mid-2021 as planned and sees the Compan...
2021-02-10 19:00
8130
Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials
NEW YORK, Feb. 9, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson's di...
2021-02-09 21:53
3475
Week's Top Stories
Most Reposted
Cornerstone Robotics Raises over US$70 million Funding to Forge Accessibility in Robotic Surgery
[Picked up by 323 media titles]
2025-01-13 09:05
URBAN REVIVO Celebrates Lunar New Year with Unique Collaboration with Artist Mercedes Bellido
[Picked up by 293 media titles]
2025-01-13 10:44
Gen Z Travelers Drive Buy Now, Plan Later Travel Bookings by Over 20%: Fliggy's 2024 Buy Now Plan Later Travel Insight
[Picked up by 286 media titles]
2025-01-10 16:04RuggON Launches VIKING II: Transforming Fleet Management with Unmatched Technology and Flexibility
[Picked up by 286 media titles]
2025-01-14 21:00
VANTAGE FOUNDATION SUPPORTS GRAB INDONESIA IN EMPOWERING WOMEN DRIVER-PARTNER
[Picked up by 280 media titles]
2025-01-09 18:26
Most Read
Hyundai Motor Group Partners with NVIDIA to Accelerate Development of AI Solutions for Future Mobility
2025-01-10 01:00
20322
AIMA Unveils Game-Changing 2025 eBike Lineup at CES: Better Performance, More Freedom
2025-01-09 02:34
6480
RingConn Takes Center Stage at CES 2025 with Innovative Wearables: Gen 2 and Gen 2 Air
2025-01-11 01:00
5610
Boqii Announces ADS Ratio Change
2025-01-11 05:30
4945
Sino Land Included in Dow Jones Sustainability World Index
2025-01-10 22:01
4926
